TRACE-Hand: Rethinking Recovery in Minor Ischemic Stroke

Inspiration

A stroke can be classified as minor while leaving a patient struggling with everyday tasks such as buttoning a shirt, holding a pen, or using a utensil.

Traditional stroke severity scores provide important clinical information, but they may not fully capture fine hand dexterity or the patient's ability to perform daily activities.

This creates a critical question: Are we measuring how well a patient has recovered, or only how mild the initial stroke appeared?

TRACE-Hand was inspired by this gap between neurological severity and functional independence. The project explores how longitudinal clinical assessments, supported by carefully separated biological research, could provide a more meaningful picture of hand recovery after minor ischemic stroke.

What it does

TRACE-Hand stands for Trajectory-Based Recovery Assessment for Clinical Evaluation of the Hand.

It is a proposed, function-first research framework designed to track hand recovery over time while distinguishing transient ischemic attacks from tissue-confirmed minor ischemic strokes.

Its two-layer model separates clinical assessment from exploratory biological research.

Layer 1 — Clinical Assessment

• Tracks upper-limb function using the Action Research Arm Test (ARAT) and the Fugl-Meyer Assessment of the Upper Extremity (FMA-UE).
• Evaluates fine dexterity using the Nine-Hole Peg Test.
• Considers patient-selected activities of daily living and rehabilitation exposure.
• Follows recovery trajectories rather than relying exclusively on a single baseline score.

Layer 2 — Exploratory Biology

• Investigates serum brain-derived neurotrophic factor (BDNF) and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP).
• Explores whether biological measurements contribute additional predictive information beyond clinical assessments.
• Keeps biomarker findings separate from rehabilitation-access and treatment-allocation decisions.

The proposed framework includes a 60-participant observational feasibility pilot, with Day 120 as the primary clinical evaluation milestone and follow-up extending to Day 180.

Core principle: Biological measurements may help generate research hypotheses, but they must never become barriers to rehabilitation.

How we built it

TRACE-Hand was developed as a literature-grounded theoretical framework and proposed clinical research protocol.

The research process involved:

1. Defining the clinical problem: Examining the limitations of global stroke severity scores in representing fine motor control and functional independence.
2. Reviewing existing evidence: Studying stroke rehabilitation, neuroplasticity, cortico-motoneuronal pathways, microglial responses, BDNF–TrkB signaling, and the limitations of peripheral biomarkers.
3. Designing the framework: Establishing separate clinical and exploratory biological layers with an explicit boundary against biomarker-based care allocation.
4. Developing the study protocol: Proposing eligibility criteria, longitudinal assessment visits, feasibility endpoints, and two falsifiable predictive hypotheses.
5. Planning future evaluation: Defining a feasibility-first approach before any potential controlled implementation study.

The proposed schedule includes baseline assessment around Days 7–14, follow-ups at Days 30, 60, 90 and 120, and a chronic follow-up at Day 180.

The framework draws on published stroke rehabilitation and biomarker research, including the PHYS-STROKE secondary biomarker analysis and established upper-limb assessment approaches.

TRACE-Hand is currently a proposed research framework. The 60-participant study has not been presented as completed, and the framework's predictive utility and clinical effectiveness remain to be established.

Challenges we ran into

1. Defining meaningful recovery

A patient may achieve an acceptable global neurological score while still experiencing difficulty with precise finger movements. Translating this clinical gap into measurable longitudinal outcomes was a central design challenge.

2. Separating clinical measurements from biological signals

BDNF and inflammatory markers may provide useful biological information, but peripheral blood measurements do not directly establish the state of brain tissue or motor-network repair. The framework therefore separates exploratory biology from clinical decisions.

3. Distinguishing TIA from minor ischemic stroke

These conditions cannot simply be grouped together in a tissue-based recovery framework. Diagnostic classification is essential to defining the intended study population and interpreting subsequent functional outcomes.

4. Designing a feasible study

The proposed 60-participant pilot must balance useful repeated measurements with participant burden, retention, standardized biological sampling, and practical clinical follow-up.

Accomplishments that we're proud of

• Developed a clearly structured two-layer framework that prioritizes functional assessment while protecting equitable access to rehabilitation.
• Integrated clinical motor assessments, fine dexterity testing, daily-activity goals, and exploratory biological measurements into a longitudinal protocol.
• Defined a proposed Day 120 primary clinical evaluation milestone within a 180-day observation plan.
• Formulated two testable hypotheses addressing the predictive value of early clinical trajectories and the incremental value of blood biomarkers.
• Established a feasibility-first research pathway that separates initial observational evaluation from any subsequent controlled implementation.

Our most important accomplishment is a clear research principle: measure functional recovery directly, investigate biomarkers responsibly, and never let an unvalidated biomarker determine access to care.

These accomplishments describe the proposed framework and protocol, not demonstrated clinical outcomes.

What we learned

Developing TRACE-Hand highlighted several important lessons.

First, a measurement can be clinically useful without capturing every dimension of a patient's recovery. Functional assessments must complement, rather than simply duplicate, global severity scores.

Second, biological plausibility is not the same as predictive validity. A biomarker associated with neuroplasticity cannot automatically be treated as a reliable measure of individual recovery.

Third, study design matters as much as the underlying scientific hypothesis. Clear diagnostic criteria, standardized assessment schedules, well-defined endpoints, and appropriate statistical comparisons are essential for producing interpretable evidence.

Finally, an equitable research framework should ensure that promising biological investigations complement clinical care rather than restrict it.

What's next for TRACE-Hand

The next step is to refine the protocol and evaluate its feasibility through a prospective observational pilot, subject to appropriate clinical collaboration, ethics approval, and resources.

Planned next steps include:

1. Finalize the protocol, eligibility criteria, assessment procedures, and standardized biomarker collection methods.
2. Establish clinical collaborations and obtain the necessary ethics and governance approvals.
3. Evaluate recruitment, participant retention, completion of the Day 120 assessment, and protocol adherence.
4. Test whether early clinical recovery trajectories improve prediction of Day 120 functional outcomes compared with baseline assessments alone.
5. Examine whether exploratory biomarkers provide meaningful additional predictive information beyond clinical variables.
6. If feasibility, adherence, and safety are satisfactory, consider a subsequent controlled implementation study to evaluate clinical utility and real-world functional transfer.

The long-term vision is a practical, evidence-driven framework that helps researchers and clinicians understand not only how mild a stroke initially appears, but also how a patient's hand function changes over time.

TRACE-Hand: Because recovery should be measured in what people can do, not just in the score they receive.

Built With

• biomarkers
• clinical
• copy
• digital
• health
• healthcare
• innovation
• medical
• neuroscience
• rehabilitation
• research
• stroke